首页> 美国卫生研究院文献>International Journal of Molecular Sciences >The Challenge of Diagnosing Constitutional Mismatch Repair Deficiency Syndrome in Brain Malignancies from Young Individuals
【2h】

The Challenge of Diagnosing Constitutional Mismatch Repair Deficiency Syndrome in Brain Malignancies from Young Individuals

机译:核心失配缺陷综合征患者脑部恶性脑严重症的挑战

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Biallelic germline mismatch repair (MMR) gene (MLH1, MSH2, MSH6, and PMS2) mutations are an extremely rare event that causes constitutional mismatch repair deficiency (CMMRD) syndrome. CMMRD is underdiagnosed and often debuts with pediatric malignant brain tumors. A high degree of clinical awareness of the CMMRD phenotype is needed to identify new cases. Immunohistochemical (IHC) assessment of MMR protein expression and analysis of microsatellite instability (MSI) are the first tools with which to initiate the study of this syndrome in solid malignancies. MMR IHC shows a hallmark pattern with absence of staining in both neoplastic and non-neoplastic cells for the biallelic mutated gene. However, MSI often fails in brain malignancies. The aim of this report is to draw attention to the peculiar IHC profile that characterizes CMMRD syndrome and to review the difficulties in reaching an accurate diagnosis by describing the case of two siblings with biallelic MSH6 germline mutations and brain tumors. Given the difficulties involved in early diagnosis of CMMRD we propose the use of the IHC of MMR proteins in all malignant brain tumors diagnosed in individuals younger than 25 years-old to facilitate the diagnosis of CMMRD and to select those neoplasms that will benefit from immunotherapy treatment.
机译:双层种系错匹配修复(MMR)基因(MLH1,MSH2,MSH6和PMS2)突变是一种极其罕见的事件,导致构成失配缺陷(CMMRD)综合征。 CMMRD是根据儿科恶性脑肿瘤的催化,常常首次亮相。需要高度对CMMRD表型的临床认识来识别新病例。免疫组织化学(IHC)对MMR蛋白表达和微卫星不稳定性分析(MSI)的评估是第一种用于在固体恶性肿瘤中启动该综合征的研究的第一种工具。 MMR IHC显示了具有在肿瘤突变基因的肿瘤和非肿瘤细胞中没有染色的标志性图案。然而,MSI经常在脑恶性肿瘤中失败。本报告的目的是提请注意特殊的IHC型材,其表征CMMRD综合症,并通过描述具有双倍嗝MSH6种系突变和脑肿瘤的两个兄弟姐妹的情况来审查达到准确诊断的困难。鉴于CMMRD早期诊断的困难,我们提出使用MMR蛋白的IHC在诊断为25岁以下的个体的恶性脑肿瘤中,以促进CMMRD的诊断并选择将受益于免疫疗法治疗的肿瘤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号